Allakos Inc.: restructuring charge — Allakos discontinues AK006 after Phase 1 CSU failure, cuts 75% of workforce

Allakos Inc.

AK006 Phase 1 CSU study failed: mean UAS7 change -8.2 (AK006) vs -12.4 (placebo); no therapeutic activity.
Workforce reduction of ~75%; ~15 employees to explore strategic alternatives and wind-down trial.
Restructuring costs estimated $34M-$38M, majority paid H1 2025; Dec 31, 2024 cash ~$81M; June 30, 2025 cash est. $35M-$40M.
AK006 was well-tolerated with no serious adverse events, but showed no efficacy versus placebo.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Allakos Inc. announced a restructuring with charges of approximately $34 million to $38 million affecting discontinuation of AK006-related activities across clinical, manufacturing, research and administrative functions (approximately 75%).

Type: restructuring
Charge: approximately $34 million to $38 million
Affected area: discontinuation of AK006-related activities across clinical, manufacturing, research and administrative functions
Headcount: approximately 75%

Exact text from the filing

On January 27, 2025, the Company announced plans to discontinue development of AK006. As part of the corporate restructuring, the Company plans to discontinue AK006-related activities across clinical, manufacturing, research and administrative functions. The Company also plans to reduce its workforce by approximately 75%. The total costs related to discontinuing AK006-related activities and reducing the workforce are estimated to be approximately $34 million to $38 million

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-25-008992

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.